Integration of Pseudotargeted Metabolomics and Microbiomics Reveals That Hugan Tablets Ameliorate NASH with Liver Fibrosis in Mice by Modulating Bile Acid Metabolism via the Gut Microbiome

Integration of Pseudotargeted Metabolomics and Microbiomics Reveals That Hugan Tablets Ameliorate NASH with Liver Fibrosis in Mice by Modulating Bile Acid Metabolism via the Gut Microbiome

<b>Background/Objectives</b>: Non-alcoholic steatohepatitis (NASH) carries a high risk of developing hepatic fibrosis. Hugan tablets (HGTs), a traditional Chinese medicine, have exhibited potent anti-hepatic fibrosis effects, though the underlying mechanisms remain unclarified. This stud...

Full description

Saved in:
Bibliographic Details
Main Authors: Wenran Dong, Ying Wang, Huajinzi Li, Huilin Ma, Yingxi Gong, Gan Luo, Xiaoyan Gao
Format: Article
Language:English
Published: MDPI AG 2025-06-01
Series:Metabolites
Subjects:
Hugan tablets
nonalcoholic steatohepatitis
hepatic fibrosis
metabolomics
gut microbiome
bile acids
Online Access:https://www.mdpi.com/2218-1989/15/7/433
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items